[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1542
1. Zhao XS, Sun Zq, Jiang B, Wang de B: [The assay of intracelluar cytidine deaminase activity and its clinical significance in patient with acute leukemia]. Beijing Da Xue Xue Bao; 2008 Apr;40(2):181-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The assay of intracelluar cytidine deaminase activity and its clinical significance in patient with acute leukemia].
  • OBJECTIVE: To investigate the relationship between the intracellular cytidine deaminase (CDD) activity and drug resistance in acute leukemia (AL) of different stage.
  • RESULTS: CDD activity of previously untreated and refractory/relapse AL patients was much higher than that of patients in complete remission (P<0.05).
  • [MeSH-major] Cytidine Deaminase / metabolism. Drug Resistance, Neoplasm. Intracellular Fluid / enzymology. Leukemia / enzymology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / pharmacology. Cytarabine / pharmacology. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458696.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


2. Wettergren L, Sprangers M, Björkholm M, Langius-Eklöf A: Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument. Psychooncology; 2008 Apr;17(4):338-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / psychology. Hodgkin Disease / therapy. Leukemia, Myeloid, Acute / therapy. Lymphoma, Non-Hodgkin / therapy. Multiple Myeloma / therapy. Quality of Life / psychology
  • [MeSH-minor] Adaptation, Psychological. Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Personality Inventory / statistics & numerical data. Psychometrics. Reference Values. Remission Induction. Sick Role. Sickness Impact Profile


3. Fang YH, Liu HX, Tong CR: [Long-term survival analysis in 89 adult patients with acute myeloid leukemia of fusion gene aml1/eto positive]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):750-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival analysis in 89 adult patients with acute myeloid leukemia of fusion gene aml1/eto positive].
  • This study was aimed to investigate various factors influencing long-term survival in adult AML patients with fusion gene aml1/eto positive.
  • Newly diagnosed 89 adult AML patients with aml1/eto positive were followed up for 1 to 42 months (median 24 months) from January 2004 to July 2008.
  • Univariate and multivariate analysis of potential factors influencing survival and prognosis were carried out by using Log-Rank and Cox regression method, including sex, age, initial WBC counts, extramedullary leukemic disease, central nervous system leukemia (CNSL), chromosome aberrations, immunophenotype, first induction regimen, chemotherapy course to complete remission (CR), time from induction therapy to CR, negative or positive rate of aml1/eto and allogeneic hematopoietic stem cell transplantation and so on.
  • Univariate analysis revealed that initial WBC counts, CNSL, chemotherapy course to CR, time from induction therapy to CR, persistent negative in remission and allogeneic hematopoietic stem cell transplantation were important prognostic factors for long-term surviva1.
  • Multivariate study demonstrated that initial WBC counts, CNSL, CD56 positive, negative or positive rate of aml1/eto, time from induction therapy to CR, persistent negative result of RT-PCR assay in remission and allogeneic hematopoietic stem cell transplantation were all critical factors in relation to OS and RFS.
  • It is concluded that Chinese adult AML patients with fusion gene aml1/eto positive have some different characteristics as compared with patients from other countries, a relatively poor outcome is observed in patients, HSCT should be recommended to adult AML patients.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549401.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


Advertisement
4. Nagasaki A, Taira N, Tomoyose T, Miyagi T, Nakachi S, Shinzato O, Hasegawa H, Takasu N: [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy]. Gan To Kagaku Ryoho; 2006 May;33(5):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].
  • Cases of adult T-cell leukemia (ATL) with aberrant phenotypes have a very poor prognosis.
  • We report the development of acute type, CD 8 positive ATL in a carrier of hepatitis B virus (HBV).
  • A diagnosis of acute type, CD 8 positive ATL was made.
  • Subsequently, he was treated with 6 cycles of CHOP and went into remission.
  • He maintained clinical remission during a follow-up of 13 months and then relapsed.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD8-Positive T-Lymphocytes / immunology. Carrier State / immunology. Hepatitis B / immunology. Lamivudine / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685173.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / HTLV-I Antibodies; 0 / Nitrosourea Compounds; 2T8Q726O95 / Lamivudine; 395575MZO7 / Pentostatin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; RYH2T97J77 / ranimustine; VB0R961HZT / Prednisone; XT3Z54Z28A / Camptothecin; CHOP protocol
  •  go-up   go-down


5. Uozumi K: Treatment of adult T-cell leukemia. J Clin Exp Hematop; 2010;50(1):9-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult T-cell leukemia.
  • Adult T-cell Leukemia (ATL) is an aggressive malignant disease of CD4+ T-cells associated with human T-cell leukemia virus type I (HTLV-I).
  • Treatment of the aggressive forms (acute and lymphoma types) of ATL remains inadequate, as most ATL patients receive conventional chemotherapy without stem cell rescue.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Graft vs Host Disease. Human T-lymphotropic virus 1. Humans. Remission Induction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505272.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


6. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J, Xu H: Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol; 2009 Nov;158(2):199-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia.
  • In this study, we investigated Th17 cell frequency and secretion of related cytokines in patients with acute myeloid leukaemia (AML).
  • Secondly, we found that the increased Th17 cell frequencies were reduced when patients achieved complete remission after chemotherapy, suggesting that measurement of Th17 cell frequencies may have clinical value in the evaluation of therapeutic effect.
  • [MeSH-major] Interleukin-17 / blood. Leukemia, Myeloid, Acute / immunology. T-Lymphocyte Subsets / immunology. T-Lymphocytes, Helper-Inducer / immunology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Flow Cytometry / methods. Humans. Interleukin-6 / blood. Male. Middle Aged. Remission Induction. Transforming Growth Factor beta / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2001 Jun;56(6):487-93 [11359967.001]
  • [Cites] Blood. 2001 Feb 1;97(3):624-30 [11157477.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2620-7 [12411307.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):452-5 [14744755.001]
  • [Cites] J Cell Mol Med. 2003 Oct-Dec;7(4):472-4 [14754516.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] AIDS. 1990 Apr;4(4):367-8 [2350458.001]
  • [Cites] Exp Cell Res. 1992 Jul;201(1):160-73 [1612121.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2457-64 [15781662.001]
  • [Cites] Int Arch Allergy Immunol. 2005;137 Suppl 1:51-4 [15947485.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] J Leukoc Biol. 2005 Oct;78(4):946-53 [16033813.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1133-41 [16200068.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Immunity. 2006 Feb;24(2):179-89 [16473830.001]
  • [Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]
  • [Cites] Nature. 2006 May 11;441(7090):231-4 [16648837.001]
  • [Cites] Nature. 2006 May 11;441(7090):235-8 [16648838.001]
  • [Cites] Cell. 2006 Sep 22;126(6):1121-33 [16990136.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2817-29 [16947782.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6730-3 [17513719.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):950-7 [17676044.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):2936-46 [17763419.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3804-13 [17693581.001]
  • [Cites] Immunity. 2008 Apr;28(4):445-53 [18400187.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):650-7 [18454150.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):641-9 [18454151.001]
  • [Cites] Blood. 2008 Jul 15;112(2):362-73 [18354038.001]
  • [Cites] Nature. 2008 Jul 17;454(7202):350-2 [18469800.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 26;374(3):533-7 [18655770.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):942-9 [17676045.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):933-44 [12461566.001]
  • (PMID = 19737137.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-17; 0 / Interleukin-6; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2768809
  •  go-up   go-down


7. Konik A, Dührsen U, Röth A: Nodular lesions of the scalp and a mediastinal mass in T cell acute lymphoblastic leukemia. Int J Hematol; 2010 Jul;92(1):3-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular lesions of the scalp and a mediastinal mass in T cell acute lymphoblastic leukemia.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Humans. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Remission Induction. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20559760.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Gorin NC, Labopin M, Boiron JM, Theorin N, Littlewood T, Slavin S, Greinix H, Cahn JY, Alessandrino EP, Rambaldi A, Nagler A, Polge E, Rocha V, Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation: Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol; 2006 Aug 20;24(24):3959-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation.
  • PURPOSE: Nucleated cell dose is an important and modifiable factor in hematopoietic stem cell transplantation (HSCT), however its association with outcomes in the context of reduced intensity conditioning regimen (RIC) HSCT for adults with acute myelocytic leukemia (AML) is not known.
  • One hundred forty one patients received transplants in first remission (CR1), 47 received transplants in second remission (CR2), and 65 patients received transplants in a more advanced phase.
  • RESULTS: Overall, 2-year leukemia-free survival (LFS) was 41% +/- 4% and it was 46% +/- 5% for patients receiving a higher cell dose (> 9.1x 10(8)/kg) and 37% +/- 5% for the remainders (P = .03).
  • [MeSH-major] Antigens, CD34. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / surgery. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Europe. Female. Graft vs Host Disease / etiology. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880451.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


9. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, Tallman MS: Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer; 2010 Nov 1;116(21):5012-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.
  • BACKGROUND: Patients with newly diagnosed acute myeloid leukemia (AML) often have residual leukemia in the bone marrow 10 to 14 days after the start of induction therapy.
  • Some cooperative groups administer a second cycle of similar induction therapy on Day 14 if there is residual leukemia.
  • It is a common perception that the presence of residual leukemia at that point predicts a worse prognosis irrespective of the therapy received.
  • The objective of this study was to determine whether patients who required a second cycle of induction (given on or about Day 14) to achieve complete remission (CR) had a worse prognosis than patients who achieved CR after only 1 cycle, because a worse prognosis may alter postremission therapy.
  • If residual leukemia was present in the bone marrow on the Day 14 after the start of induction, then patients were to receive a second cycle of identical induction therapy.
  • CONCLUSIONS: The presence of residual leukemia in bone marrow 10 to 14 days after induction therapy did not predict a worse prognosis if patients received second, similar cycle of induction therapy and achieved CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm, Residual / drug therapy. Prognosis. Remission Induction. Retreatment

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] Blood. 1995 Jul 15;86(2):457-62 [7605984.001]
  • [Cites] Am J Hematol. 1994 Nov;47(3):172-7 [7942780.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Lancet. 1998 Mar 7;351(9104):700-8 [9504514.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Br J Haematol. 2006 Jul;134(1):54-7 [16803567.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4172-4 [17909077.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):181-93 [17996460.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Am J Hematol. 2008 Jun;83(6):446-50 [18247382.001]
  • [Cites] Leukemia. 1996 Jun;10(6):932-6 [8667647.001]
  • [Cites] Blood. 2000 Jan 1;95(1):72-7 [10607687.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3254-61 [12149299.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2393-8 [12239147.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2717-23 [12351377.001]
  • [Cites] Blood. 2003 Jan 1;101(1):64-70 [12393605.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Blood. 2004 Jan 15;103(2):479-85 [14512295.001]
  • [Cites] Haematologica. 2004 Aug;89(8):926-33 [15339675.001]
  • [Cites] Br J Haematol. 2004 May;125(4):477-9 [15142118.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Leuk Res. 1983;7(1):67-75 [6572773.001]
  • [Cites] J Clin Oncol. 1984 Feb;2(2):107-11 [6699661.001]
  • [Cites] Leuk Res. 1988;12(10):817-21 [3199841.001]
  • [Cites] Br J Haematol. 1989 Apr;71(4):493-7 [2653407.001]
  • [Cites] Leukemia. 1990 Mar;4(3):184-8 [2314117.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):314-9 [8426209.001]
  • [CommentIn] Cancer. 2010 Nov 1;116(21):4896-901 [20623787.001]
  • (PMID = 20629023.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA013650; United States / NCI NIH HHS / CA / U10 CA014548; United States / NCI NIH HHS / CA / U10 CA014958; United States / NCI NIH HHS / CA / U10 CA017145; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA023318; United States / NCI NIH HHS / CA / U10 CA066636; United States / NCI NIH HHS / CA / U24 CA114737
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS435496; NLM/ PMC3566633
  •  go-up   go-down


10. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C, Glass J, Munker R: Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol; 2005 Apr;78(4):288-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature.
  • Primary plasma cell leukemia (PPCL) is a rare hematologic malignancy characterized by the proliferation of plasma cells in blood, bone marrow, and other organs in the absence of established multiple myeloma.
  • The first case was diagnosed in a 21-year-old male who presented with leukocytosis and acute renal failure.
  • He was treated with hyper-CVAD, entered complete remission, and then proceeded to high-dose chemotherapy with peripheral stem-cell support.
  • He is currently in complete remission 23 months after initial diagnosis and 19 months after autologous SCT.
  • He remained in complete remission for 3 years and then developed progressive refractory disease, dying 7 years after the initial diagnosis.
  • [MeSH-major] Leukemia, Plasma Cell / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Humans. Male. Middle Aged. Prognosis. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15795922.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


11. Weir EG, Ali Ansari-Lari M, Batista DA, Griffin CA, Fuller S, Smith BD, Borowitz MJ: Acute bilineal leukemia: a rare disease with poor outcome. Leukemia; 2007 Nov;21(11):2264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute bilineal leukemia: a rare disease with poor outcome.
  • Most cases of acute leukemia can be assigned to the myeloid, B or T lineage.
  • A subset of these, referred to as acute bilineal leukemias (aBLLs), is characterized by the presence of more than one population of blasts, each comprising a single lineage.
  • Of 16 patients with outcome data, only six achieved complete remission and only two remain free of disease 2.5 and 4.5 years after chemotherapy or stem cell transplantation. aBLL is a rare disease that combines B or T and myeloid blasts.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / diagnosis. Leukemia, Biphenotypic, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cytogenetics. Female. Humans. Immunophenotyping. Infant. Karyotyping / methods. Male. Middle Aged. Remission Induction. Translocation, Genetic. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611554.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Stone RM: New agents in post-remission therapy. Best Pract Res Clin Haematol; 2010 Dec;23(4):475-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New agents in post-remission therapy.
  • The choice of post-remission therapy for patients with acute myeloid leukemia (AML) depends on age, response to initial therapy, and on disease-related biology.
  • High-dose ara-C (HIDAC) is the standard chemotherapy-based post-remission treatment for younger AML patients, but diagnostic cytogenetics and genetic features may mandate an allogeneic stem cell transplant.
  • While intensive chemotherapy has little utility, the optimal post-remission therapy for older adults remains unclear, though reduced-intensity conditioning allogeneic stem cell transplant is being used with increasing frequency.
  • [MeSH-major] Leukemia, Myeloid, Acute
  • [MeSH-minor] Adult. Age Factors. Aged. Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Male. Middle Aged. Remission Induction / methods. Stem Cell Transplantation. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ltd.
  • (PMID = 21130410.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


13. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Turlure P, Reman O, Gardin C, Varet B, de Botton S, Pousset F, Farhat H, Chevret S, Dombret H, Castaigne S: High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia; 2007 Jan;21(1):66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
  • Pivotal phase II studies in acute myeloblastic leukemia (AML) patients in first relapse have used gemtuzumab ozogamicin (GO) (Mylotarg) at a dose of 9 mg/m(2) on days 1 and 14.
  • These studies showed a 26% response rate (13% complete remission (CR) and 13% CRp (complete remission with incomplete platelet recovery)) but with high degree of hematological and liver toxicities.
  • Remission rate correlated strongly with P-glycoprotein and MRP1 activities.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antigens, CD / blood. Antigens, Differentiation, Myelomonocytic / blood. Disease-Free Survival. Drug Administration Schedule. Humans. Middle Aged. Multidrug Resistance-Associated Proteins / blood. P-Glycoprotein / blood. Recurrence. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051246.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab; 0 / multidrug resistance-associated protein 1
  •  go-up   go-down


14. Gallagher RE, Schachter-Tokarz EL, Zhou DC, Ding W, Kim SH, Sankoorikal BJ, Bi W, Livak KJ, Slack JL, Willman CL: Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure. Leukemia; 2006 Apr;20(4):556-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.
  • Relapse of acute promyelocytic leukemia (APL) following all-trans retinoic acid (ATRA) therapy has been associated with the acquisition of mutations in the high-affinity ATRA binding site in PML-RARalpha, but little information is available about the selection dynamics of the mutation-harboring subclones.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1997 Nov;11(11):1950-6 [9369431.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1172-83 [9694705.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1758-67 [9716606.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]
  • [Cites] Blood. 2005 May 1;105(9):3686-90 [15626733.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9714-9 [15980154.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1109-17 [15858614.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2128-37 [15914554.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2175-81 [8400267.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1656-63 [9269786.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4282-9 [9192750.001]
  • [Cites] Blood. 1996 May 15;87(10):4399-403 [8639801.001]
  • [Cites] Leukemia. 1996 Jan;10(1):61-6 [8558940.001]
  • [Cites] Blood. 1993 Oct 1;82(7):1949-53 [8400247.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1940-58 [12357346.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1413-9 [1884013.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1995-9 [15187030.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2521-8 [12468436.001]
  • [Cites] Blood. 2003 Jul 1;102(1):276-83 [12623848.001]
  • [Cites] Blood. 1998 Jul 15;92(2):374-82 [9657734.001]
  • [Cites] Haematologica. 1999 Nov;84(11):963-8 [10553155.001]
  • [Cites] Oncogene. 1999 Dec 23;18(56):7941-7 [10637504.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3200-8 [11050004.001]
  • [Cites] Semin Hematol. 2001 Jan;38(1):13-25 [11172536.001]
  • [Cites] Exp Hematol. 2001 Jul;29(7):864-72 [11438209.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2651-6 [11675334.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2862-4 [11675363.001]
  • [Cites] J Mol Diagn. 2001 Nov;3(4):141-9 [11687597.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1356-63 [11830487.001]
  • [Cites] Science. 2002 Feb 8;295(5557):1079-82 [11834837.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1014-8 [12130516.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2586-96 [12239173.001]
  • (PMID = 16437139.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA056771; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA56771
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ NIHMS7277; NLM/ PMC1410817
  •  go-up   go-down


15. Horstmann MA, Hassenpflug WA, zur Stadt U, Escherich G, Janka G, Kabisch H: Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children. Haematologica; 2005 Dec;90(12):1701-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
  • In a retrospective analysis of 24 children with refractory or multiply relapsed acute lymphoblastic leukemia (ALL), a salvage regimen comprising amsacrine, etoposide, and high-dose methylprednisolone AEP achieved a significant treatment response in 11 of 19 evaluable patients (8 complete and 3 partial remissions).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Amsacrine / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Cytarabine / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dexamethasone / administration & dosage. Drug Evaluation. Drug Synergism. Etoposide / administration & dosage. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Idarubicin / administration & dosage. Infant. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / surgery. Male. Methylprednisolone / administration & dosage. Neoplasm, Residual. Peripheral Blood Stem Cell Transplantation. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / surgery. Prognosis. Recombinant Proteins. Remission Induction. Retrospective Studies. Survival Analysis. Thiotepa / administration & dosage. Topotecan / administration & dosage. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330449.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Recombinant Proteins; 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; 7S5I7G3JQL / Dexamethasone; 905Z5W3GKH / Thiotepa; FA2DM6879K / Vidarabine; PVI5M0M1GW / Filgrastim; X4W7ZR7023 / Methylprednisolone; ZRP63D75JW / Idarubicin; AEP protocol; Ida-FLAG protocol; TVTG protocol
  •  go-up   go-down


16. Fozza C, Szydlo RM, Abdel-Rehim MM, Nadal E, Goldman JM, Apperley JF, Dazzi F: Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br J Haematol; 2007 Mar;136(6):833-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two factors emerged as predictors of both acute and chronic GVHD: the infusion of male recipients with lymphocytes from a female donor and the interval between transplant and last DLI, but only the first remained significant at multivariate analysis.
  • [MeSH-major] Graft vs Host Disease. Leukemia, Myeloid / therapy. Lymphocyte Transfusion / methods
  • [MeSH-minor] Adult. Antigens, CD3 / immunology. Female. Humans. Logistic Models. Lymphocytes / immunology. Male. Recurrence. Remission Induction. Risk Factors. Sex Factors. Time Factors. Transplantation, Homologous

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341269.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3
  •  go-up   go-down


17. Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD: Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol; 2005 Jan 20;23(3):482-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
  • PURPOSE: Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML).
  • RESULTS: Of 350 patients receiving AD, 73% achieved complete remission (CR), compared with 82% of 140 receiving ADE/ADEP (P = .04).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics. Splenomegaly
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aziridines / administration & dosage. Benzoquinones / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Karyotyping. Male. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Recurrence. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534356.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 03927; United States / NCI NIH HHS / CA / CA 101140; United States / NCI NIH HHS / CA / CA 16058; United States / NCI NIH HHS / CA / CA 32291; United States / NCI NIH HHS / CA / CA 33601; United States / NCI NIH HHS / CA / CA 35279; United States / NCI NIH HHS / CA / CA 41287; United States / NCI NIH HHS / CA / CA 47545; United States / NCI NIH HHS / CA / CA 47577; United States / NCI NIH HHS / CA / CA 77658
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aziridines; 0 / Benzoquinones; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FQL5EUP13W / diaziquone; ZS7284E0ZP / Daunorubicin; DAV regimen
  •  go-up   go-down


18. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA; 2009 Jun 10;301(22):2349-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
  • CONTEXT: The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain.
  • STUDY SELECTION: Prospective trials assigning adult patients with AML in CR1 to undergo allogeneic SCT vs nonallogeneic SCT treatment(s) based on donor availability and trials reporting RFS and/or overall survival outcomes on an intention-to-treat, donor vs no-donor basis were identified.
  • CONCLUSION: Compared with nonallogeneic SCT therapies, allogeneic SCT has significant RFS and overall survival benefit for intermediate- and poor-risk AML but not for good-risk AML in first complete remission.


19. Fenton C, Perry CM: Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs; 2005;65(16):2405-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.
  • Gemtuzumab ozogamicin (Mylotarg) is a conjugate of a monoclonal antibody and calicheamicin, which targets the membrane antigen CD33 in CD33-positive acute myeloid leukaemia (AML) and, after cell internalisation, releases a derivative of the cytotoxic calicheamicin component.
  • Monotherapy with gemtuzumab ozogamicin results in complete remission (CR) or CR with incomplete platelet recovery (CRp) in approximately =25% of adults (including those aged > or =60 years) with CD33-positive AML in first relapse.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antibodies, Monoclonal, Humanized. Child. Clinical Trials as Topic. Drug Resistance, Neoplasm. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] BioDrugs. 2006;20(2):137-9 [16626170.001]
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):522-7 [11673694.001]
  • [Cites] Onkologie. 2004 Feb;27(1):72-82 [15007253.001]
  • [Cites] Pharmacotherapy. 2001 Oct;21(10 ):1175-80 [11601662.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1306-11 [15920495.001]
  • [Cites] Leuk Res. 2003 Oct;27(10 ):893-7 [12860008.001]
  • [Cites] Semin Hematol. 2001 Jul;38(3 Suppl 6):24-31 [11474494.001]
  • [Cites] Blood. 2004 Jan 15;103(2):479-85 [14512295.001]
  • [Cites] J Clin Pharmacol. 2001 Nov;41(11):1206-14 [11697753.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3574-80 [11369653.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4589-97 [12576328.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1490-6 [11410481.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] Drugs Aging. 2002;19(8):571-81 [12207551.001]
  • [Cites] Leukemia. 2005 Oct;19(10 ):1768-73 [16079891.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):443-50 [15231251.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]
  • [Cites] Haematologica. 2001 Aug;86(8):814-20 [11522537.001]
  • [Cites] Leukemia. 2004 May;18(5):983-8 [15029214.001]
  • [Cites] Leukemia. 2005 Feb;19(2):176-82 [15592433.001]
  • [Cites] Haematologica. 2004 Aug;89(8):998-1008 [15339685.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4276-84 [14962898.001]
  • [Cites] Leukemia. 1992 Aug;6(8):776-9 [1640728.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1295-302 [15454492.001]
  • [Cites] J Clin Pharmacol. 2004 Aug;44(8):873-80 [15286091.001]
  • [Cites] Haematologica. 2004 Aug;89(8):950-6 [15339678.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 1:i48-9 [15888751.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Dec;52(6):449-52 [13680159.001]
  • [Cites] Leukemia. 2003 Mar;17(3):492-5 [12646936.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1578-82 [12738663.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2310-4 [11895761.001]
  • [Cites] CA Cancer J Clin. 2002 Nov-Dec;52(6):363-71 [12469764.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1049-55 [9665189.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1466-73 [12689934.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1627-36 [12200674.001]
  • [Cites] Leuk Res. 2005 Jan;29(1):53-7 [15541475.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1995-9 [15187030.001]
  • [Cites] Leukemia. 2002 May;16(5):813-9 [11986941.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):24-30 [11790976.001]
  • [Cites] Acta Oncol. 2001;40(2-3):231-52 [11441935.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1481-7 [12627513.001]
  • [Cites] Onkologie. 2004 Jun;27(3):269-72 [15249716.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4277-83 [12933575.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10 ):1951-5 [12481890.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):47-58 [11792178.001]
  • [Cites] Leukemia. 2004 Feb;18(2):316-25 [14614514.001]
  • [Cites] Blood. 2001 Aug 15;98 (4):988-94 [11493443.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Eur J Haematol. 2002 Oct;69(4):200-4 [12431238.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):87-90 [12497211.001]
  • [Cites] Drugs. 2001;61(9):1317-22; discussion 1323-4 [11511025.001]
  • [Cites] Blood. 2003 May 15;101(10 ):3868-71 [12543868.001]
  • (PMID = 16266206.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 93NS566KF7 / gemtuzumab
  • [Number-of-references] 72
  •  go-up   go-down


20. Jeddi R, Mansouri R, Kacem K, Gouider E, Abid HB, Belhadjali Z, Meddeb B: Transfusion-related acute lung injury (TRALI) during remission induction course of acute myeloid leukemia: a possible role for all-transretinoic-acid (ATRA)? Pathol Biol (Paris); 2009 Sep;57(6):500-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transfusion-related acute lung injury (TRALI) during remission induction course of acute myeloid leukemia: a possible role for all-transretinoic-acid (ATRA)?
  • Transfusion-related acute lung injury (TRALI) is a clinical syndrome characterized by sudden onset of respiratory distress due to pulmonary edema during or following transfusion.
  • We report a case of TRALI occurring during remission induction course of acute myeloid leukemia in a 27-year-old woman who received All-transretinoic-acid (ATRA).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blood Transfusion / adverse effects. Leukemia, Myeloid, Acute / therapy. Leukocytosis / etiology. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Anemia / etiology. Female. Flow Cytometry. Humans. Remission Induction / methods. Respiratory Distress Syndrome, Adult / etiology


21. Achiron A, Feldman A, Mandel M, Gurevich M: Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci; 2007 Jun;1107:155-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse.
  • Differential expression of apoptotic genes may influence the susceptibility of activated lymphocytes to expand and induce acute relapse and persistent inflammation in patients with relapsing-remitting multiple sclerosis (RRMS).
  • In this study we studied peripheral blood mononuclear cells (PBMCs) expression of pro- and antiapoptotic genes in RRMS patients during acute relapse in comparison to patients in remission.
  • Using cDNA Affymetrix microarrays platform (U133A2 microarrays) we analyzed the gene expression profile of PBMC derived from 22 RRMS patients in acute relapse (15 females, mean age 34.6 +/- 1.8 years, disease duration 5.6 +/- 0.8 years) in comparison to 20 sex- and age-matched RRMS patients in remission.
  • One thousand five hundred seventy-eight gene transcripts significantly differentiated acute multiple sclerosis (MS) relapse from remission.
  • The 1578 gene transcripts that significantly differentiated acute relapse from remission were enriched by 55 apoptotic-related genes in that reflected different operating pathways during the acute phase of the disease.
  • An additional group of antiapoptotic genes related to T cell receptor-mediated apoptosis was also found to be overexpressed in acute relapse and included TCR-binding CD3E antigen, antiapoptotic serine threonin kinase (AKT), and NF kappa B-associated genes like reticuloendotheliosis viral oncogene homolog A (RELA) and human T cell leukemia virus type I-binding protein (Tax1BP) known to inhibit tumor necrosis factor (TNF)-induced apoptosis.
  • Our findings demonstrate impaired apoptotic mechanisms in peripheral lymphocytes from RRMS patients during acute relapse.
  • [MeSH-minor] Acute Disease / classification. Adult. Female. Gene Expression Profiling. Humans. Male. RNA, Messenger / genetics. RNA, Messenger / metabolism. Recurrence


22. Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, Tanosaki R, Takahashi S, Matsushima T, Atsuta Y, Hamajima N, Kasai M, Kato S: Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia; 2005 Mar;19(3):396-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cumulative incidence of grade II-IV acute GVHD was 33%.
  • OS at 5 years was 57% for patients who underwent allo-SCT as a primary treatment for refractory anemia with excess blasts in transformation (RAEB-t) or secondary acute myeloid leukemia (AML) and 54% for those who underwent allo-SCT in remission after induction chemotherapy (P=0.81).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Graft vs Host Disease / therapy. Histocompatibility. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Siblings. Survival Analysis. Transplantation Conditioning. Transplantation, Homologous


23. Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, Tanosaki R, Utsunomiya A, Uike N, Yoshida S, Okamura J, Tomonaga M: Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia; 2005 May;19(5):829-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy.
  • To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002.
  • All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Analysis of Variance. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / therapy. Humans. Japan / epidemiology. Male. Middle Aged. Reproducibility of Results. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744352.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


24. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O: Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol; 2010 Mar;84(3):239-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
  • OBJECTIVES: Angiogenesis seems important for both leukemogenesis and chemosensitivity in acute myelogenous leukemia (AML).
  • Patients achieving complete hematological remission after only one induction cycle showed relatively low constitutive MMP-2 release.
  • [MeSH-major] Leukemia, Myeloid / pathology. Matrix Metalloproteinases / secretion. Neoplasm Proteins / secretion. Tissue Inhibitor of Metalloproteinases / secretion
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Angiopoietin-2 / pharmacology. Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / pharmacology. Bortezomib. Cells, Cultured / cytology. Chemokines / secretion. Coculture Techniques. Culture Media, Serum-Free / pharmacology. Cytarabine / administration & dosage. Diterpenes / pharmacology. Endothelial Cells / cytology. Female. Humans. Imidazoles / pharmacology. Male. Matrix Metalloproteinase Inhibitors. Middle Aged. NF-kappa B / antagonists & inhibitors. Protease Inhibitors / pharmacology. Pyrazines / pharmacology. Quinoxalines / pharmacology. Receptor, TIE-2 / antagonists & inhibitors. Receptor, TIE-2 / physiology. Recombinant Proteins / pharmacology. Tumor Cells, Cultured / enzymology. Tumor Cells, Cultured / secretion

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922462.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-ingenyl angelate; 0 / 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline; 0 / Angiopoietin-2; 0 / Anthracyclines; 0 / Boronic Acids; 0 / Chemokines; 0 / Culture Media, Serum-Free; 0 / Diterpenes; 0 / Imidazoles; 0 / Matrix Metalloproteinase Inhibitors; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / Quinoxalines; 0 / Recombinant Proteins; 0 / Tissue Inhibitor of Metalloproteinases; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; EC 2.7.10.1 / Receptor, TIE-2; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


25. Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N: A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol; 2009 Dec;147(5):691-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).
  • Sirolimus has been shown to have activity against human acute lymphoblastic leukaemia at serum levels used for immunosuppression.
  • The study cohort included 18 patients in high-risk (HR) first complete remission (CR1), 16 in HR CR2, 17 in intermediate risk (IR) CR2, and 12 in CR3+.
  • Cumulative incidence of acute GVHD grade II-IV and III-IV was 38% and 21% respectively, while the cumulative incidence of chronic GVHD was 32%.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1149-55 [16195324.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1112-5 [17473063.001]
  • [Cites] Eur J Clin Invest. 2008 Jan;38(1):43-52 [18173550.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):66-70 [18307022.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 May;14(5):531-7 [18410895.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S39-42 [18545243.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Aug;14(8):920-6 [18640576.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2020-3 [18544682.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4425-31 [18776081.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5767-74 [19001324.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):62-71 [19147081.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):377-84 [19064980.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6A):3801-8 [19189667.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Nat Med. 2002 Feb;8(2):128-35 [11821896.001]
  • [Cites] Blood. 2002 May 1;99(9):3151-7 [11964277.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Dec;24(9):746-50 [12468917.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2043-8 [12406916.001]
  • [Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]
  • [Cites] Blood. 2003 May 15;101(10):3835-9 [12732501.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1601-5 [12730113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(6):471-6 [15273708.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):255-67 [8420443.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Jul;11(7):551-7 [15983555.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Aug;11(8):571-5 [16041306.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1396-404 [16219577.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • (PMID = 19744131.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116660-04; United States / NCI NIH HHS / CA / R01 CA116660; United States / NCI NIH HHS / CA / CA116660-04; United States / NCI NIH HHS / CA / R01 CA102646; United States / NCI NIH HHS / CA / R01 CA102646-05; United States / NCI NIH HHS / CA / CA102646-05; United States / NCI NIH HHS / CA / CA102646; United States / NCI NIH HHS / CA / CA1116660
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ NIHMS209799; NLM/ PMC2888481
  •  go-up   go-down


26. Baek JH, Sohn SK, Kim DH, Kim JG, Yang DH, Kim YK, Lee JJ, Kim HJ: Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia. Acta Haematol; 2007;117(2):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
  • BACKGROUND: The sensitization of leukemic cells with hematopoietic growth factors can enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML).
  • Intensified remission induction (RI) therapy can also improve the treatment results for AML.
  • The complete remission rate and treatment-related mortality were 72 and 17% for the G-CSF-primed group (p = 0.89) and 71 and 10% for the historical group (p = 0.32), respectively.
  • [MeSH-major] Cytarabine / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Idarubicin / administration & dosage. Leukemia, Myeloid / drug therapy. Remission Induction / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Hematopoietic Stem Cell Mobilization. Humans. Male. Middle Aged. Pilot Projects. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17135724.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; ZRP63D75JW / Idarubicin
  •  go-up   go-down


27. Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, Molina L, Fegueux N, Pigneux A, Recher C, Rossi JF, Attal M, Sotto JJ, Maraninchi D, Reiffers J, Bardou VJ, Esterni B, Blaise D: Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol; 2005 Oct 20;23(30):7676-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.
  • PURPOSE: We analyzed the impact of allogeneic stem-cell transplantation (alloSCT) as an early consolidation for young patients with acute myeloblastic leukemia in first complete remission (CR1) through four successive protocols.
  • [MeSH-major] Leukemia, Myeloid / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Remission Induction. Time Factors. Tissue and Organ Procurement. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186596.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


28. Li Y, Zou D, Zhao Y, Mi Y, Wang J, Qiu L: Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China. Leuk Lymphoma; 2010 Mar;51(3):488-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China.
  • The study reviewed 389 adult patients with acute lymphoblastic leukemia (ALL) and 110 patients (28.3%) were diagnosed as Philadelphia chromosome positive (Ph-positive) and/or bcr-abl positive ALL.
  • The complete remission (CR) rate in conventional chemotherapy (CT) group and in chemotherapy combined with imatinib (ICT) group was 84.7% and 96.0%, respectively.
  • [MeSH-major] Fusion Proteins, bcr-abl / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / pharmacology. Pyrimidines / pharmacology. Retrospective Studies. Stem Cell Transplantation. Transplantation, Homologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141436.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


29. Ziegler DS, Dalla Pozza L, Waters KD, Marshall GM: Advances in childhood leukaemia: successful clinical-trials research leads to individualised therapy. Med J Aust; 2005 Jan 17;182(2):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cure rates for acute lymphoblastic leukaemia (ALL) now approach 80%.
  • A high level of minimal residual disease detected by polymerase chain reaction in patients with ALL in remission has profound prognostic importance and is the focus of a major Australian study attempting to prevent relapse in these children.
  • Adolescents with ALL have a better prognosis if treated with paediatric rather than adult protocols.
  • [MeSH-major] Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation / adverse effects. Child. Cranial Irradiation / adverse effects. Humans. Leukemia / diagnosis. Leukemia / physiopathology. Leukemia / therapy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15651967.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 45
  •  go-up   go-down


30. Yanada M, Matsuo K, Suzuki T, Naoe T: Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer; 2006 Jun 15;106(12):2657-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis.
  • BACKGROUND: The prognosis for adult patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory primarily because of the high incidence of recurrence.
  • METHODS: Rigorous criteria were used to select 7 studies of adult ALL that prospectively assessed overall survival (OS) using natural randomization based on donor availability combined with intention-to-treat analyses.
  • CONCLUSIONS: The current findings demonstrated that allogeneic HSCT improves the outcome of adult patients with high-risk ALL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Humans. Incidence. Prognosis. Remission Induction / methods. Secondary Prevention. Survival Rate. Transplantation, Homologous. Treatment Outcome


31. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE: A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood; 2007 Feb 15;109(4):1387-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
  • Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors.
  • Complete remission (CR) was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in 15 patients, for an overall response rate of 23%.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7514-26 [10602510.001]
  • [Cites] Invest New Drugs. 1999;17(3):241-58 [10665477.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1268-74 [2475589.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2847-53 [1581898.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3229-32 [8205544.001]
  • [Cites] N Engl J Med. 1995 Jun 22;332(25):1671-7 [7760868.001]
  • [Cites] Blood. 1995 Jul 15;86(2):457-62 [7605984.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1871-7 [10766174.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2318-25 [10873082.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6105-13 [10913192.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30451-7 [10852915.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Exp Cell Res. 2001 Jan 1;262(1):17-27 [11120601.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):131-7 [11196150.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):450-8 [11809695.001]
  • [Cites] Blood. 2002 Jul 1;100(1):29-35 [12070004.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3295-304 [7614464.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5302-9 [7585592.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):708-13 [9044849.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2969-77 [9376577.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Blood. 1998 May 15;91(10):3607-15 [9572995.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1439-45 [9779989.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1090-8 [16435386.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • (PMID = 17082323.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070095; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA70095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNAJA1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Quinolones; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase
  • [Other-IDs] NLM/ PMC1794070
  •  go-up   go-down


32. Deneberg S, Grövdal M, Karimi M, Jansson M, Nahi H, Corbacioglu A, Gaidzik V, Döhner K, Paul C, Ekström TJ, Hellström-Lindberg E, Lehmann S: Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia; 2010 May;24(5):932-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.
  • This study was designed to analyze the effect of global and gene-specific DNA methylation patterns on the outcome of patients with acute myeloid leukemia (AML).
  • In multivariate analysis, low global DNA methylation was associated with higher complete remission rate (hazard ratio (HR) 5.9, P=0.005) and p15 methylation was associated with better overall (HR 0.4, P=0.001) and disease-free survival (HR 0.4, P=0.016).
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA Methylation. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cadherins / genetics. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Promoter Regions, Genetic. Remission Induction. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20237504.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p15
  •  go-up   go-down


33. Jiang B, Mi YC, Lin D, Cai XJ, Fu MW, Li W, Wang Y, Liu XP, Xue YP, Bian SG, Wang JX: [A new prognostic stratification for patients with acute myeloid leukemia]. Zhonghua Nei Ke Za Zhi; 2009 Apr;48(4):316-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A new prognostic stratification for patients with acute myeloid leukemia].
  • OBJECTIVE: To evaluate the impact of the percentage of residual blasts in bone marrow at the end of induction chemotherapy (T1) or during myelosuppression phase (T2) on prognosis of de novo acute myeloid leukemia (AML) (non M(3)) in 105 cases.
  • Patients with percentage of residual bone marrow blast cells < 5% had better complete remission (CR) rate, relapse-free survival (RFS) and overall survival (OS) than the patients with percentage > or = 5% at T1 or T2.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Cytogenetics. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576124.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


34. Imataki O, Koike A, Iwabu M, Shintani T, Waki F, Ohue Y, Ohnishi H, Ishida T: [Limited but potential efficacy by graft-versus-leukemia (GVL) for Pro T-ALL]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1911-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limited but potential efficacy by graft-versus-leukemia (GVL) for Pro T-ALL].
  • We present a 22-year-old male diagnosed with pro T-acute lymphoblastic leukemia (ALL).
  • The patient was treated with induction therapy followed by 3 courses of consolidation therapy and achieved his first complete remission.
  • [MeSH-major] Graft vs Leukemia Effect / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Treatment Failure. Young Adult

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011341.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol; 2009 Feb 1;27(4):504-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
  • PURPOSE: We examined the outcome of patients with newly diagnosed acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) with or without gemtuzumab ozogamicin (GO) but without traditional cytotoxic chemotherapy.
  • RESULTS: Overall, 74 patients achieved complete remission (CR) and one achieved CR without full platelet recovery after the induction, for a response rate of 92%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Arsenicals / administration & dosage. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Oxides / administration & dosage. Polymerase Chain Reaction. Remission Induction. Survival Rate. Treatment Outcome. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075265.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC4881307
  •  go-up   go-down


36. Shin HJ, Chung JS, Choi YJ, Cho GJ: A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia. Am J Clin Oncol; 2009 Jun;32(3):227-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia.
  • OBJECTIVES: Priming with granulocyte macrophage colony-stimulating factor (GM-CSF) plus all-trans retinoic acid (ATRA) during induction chemotherapy may enhance response rates and survival in patients with acute myeloid leukemia (AML) due to the differentiation of human myeloblastic leukemia cells into granulocytes.
  • RESULTS: For patients enrolled in this study, the complete remission plus complete remission with incomplete platelet recovery rate was 61.5% as compared with 41.4% for the historical control group of subjects.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Pilot Projects. Prognosis. Remission Induction. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433969.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


37. Chen YX, Wang WP, Zhang PY, Zhang WG, Liu J, Ma XR: [Expression of genes psma6 and slc25a4 in patients with acute monocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct;17(5):1168-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of genes psma6 and slc25a4 in patients with acute monocytic leukemia].
  • The aim of this study was to investigate the expression levels of genes psma6 and slc25a4 in bone marrow of patients with acute monocytic leukemia and their correlation with clinical features and prognosis.
  • The expression levels of genes psma6 and slc25a4 in AML-M5 leukemia cells, normal blood cells and non-leukemia cells were detected by real-time quantitative RT-PCR and compared each other.
  • The results showed that the expression levels of psma6 mRNA in AML-M5 leukemia cells was lower than that in non AML-M5 leukemia cells, non-leukemia cells and normal blood cells.
  • The expression level of psma6 in AML-M5 patients with complete remission was higher than that in AML-M5 patients without remission.
  • The overexpression of slc25a4 mRNA was found in AML-M5, but there was no significant difference in slc25a4 mRNA expression between the patients with complete remission and those without remission.
  • It is concluded that the expression level of psma6 is probably a new prognostic indicator of acute monocytic leukemia, slc25a4 may be a novel gene of antigen associated with acute monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840444.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 1; EC 3.4.25.1 / PSMA6 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


38. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD: Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol; 2009 Jul 1;27(19):3198-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
  • PURPOSE To determine the prognostic importance of the meningioma 1 (MN1) gene expression levels in the context of other predictive molecular markers, and to derive MN1 associated gene- and microRNA-expression profiles in cytogenetically normal acute myeloid leukemia (CN-AML).
  • Patients were intensively treated on two first-line Cancer and Leukemia Group B clinical trials.
  • In multivariable analyses, higher MN1 expression associated with a lower complete remission rate (P = .005) after adjustment for WBC; shorter disease-free survival (P = .01) after adjustment for WT1 mutations, FLT3 internal tandem duplications (FLT3-ITD), and high ERG expression; and shorter survival (P = .04) after adjustment for WT1 and NPM1 mutations, FLT3-ITD, and WBC.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1511-9 [7731705.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1418-25 [8640834.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2234-44 [15890672.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3747-54 [16109776.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1582-92 [16810199.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3898-905 [16912223.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5164-7 [17341662.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1679-90 [17525718.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1639-47 [17494859.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19849-54 [18056638.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] J Mol Med (Berl). 2008 Mar;86(3):313-22 [18193184.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):239-44 [18636143.001]
  • [Cites] Nat Rev Immunol. 2008 Aug;8(8):607-18 [18641646.001]
  • [Cites] Dev Cell. 2008 Aug;15(2):261-71 [18694565.001]
  • [Cites] Dev Cell. 2008 Aug;15(2):272-84 [18694566.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Oncogene. 2003 Feb 6;22(5):699-709 [12569362.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • (PMID = 19451432.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U24 CA114725; United States / NCI NIH HHS / CA / U10 CA101140; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / U10 CA003927
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAALC protein, human; 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / ERG protein, human; 0 / MLL protein, human; 0 / MN1 protein, human; 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / Tumor Suppressor Proteins; 117896-08-9 / nucleophosmin; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Other-IDs] NLM/ PMC2716941
  •  go-up   go-down


39. Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H: Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant; 2009 Nov;15(11):1376-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
  • For patients with advanced leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), a major obstacle to success, especially in those with a high leukemia cell burden, is relapse of the underlying disease.
  • To improve the outcome of allo-HSCT for refractory leukemia, we investigated the strategy of sequential intensified conditioning and early rapid tapering of prophylactic immunosuppressants therapy for graft-versus-host disease (GVHD) during the early stage after transplantation.
  • A total of 51 patients with refractory leukemia (median age, 30.0 years; unfavorable karyotypes, 49%) received fludarabine (Flu) 30 mg/m(2)/day and cytarabine 2 g/m(2)/day (on days -10 to -6), 4.5 Gy total body irradiation (TBI)/day (on days -5 and -4), and cyclophosphamide (Cy) 60 mg/kg/day and etoposide 600 mg/day (on days -3 and -2) for conditioning.
  • Cyclosporine A (CsA) was withdrawn rapidly in a stepwise fashion to avoid overwhelming GVHD reactions if acute GVHD (aGVHD) did not develop at day +30.
  • All 51 patients developed regimen-related toxicities (13 with grade III-IV); 93.9% of them achieved complete remission by day +30.
  • Thirteen patients relapsed; the 3-year cumulative incidence of leukemia relapse was 33.3%.
  • Our data indicate that the sequential strategy of cytoreductive chemotherapy followed immediately by intensified myeloablative (MA) conditioning for allo-HSCT and rapid tapering of prophylactic immunosuppressants for GVHD in the early stage after transplantation has an acceptable toxicity profile and may be a better approach to treating refractory leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / administration & dosage. Leukemia / surgery. Myeloablative Agonists / administration & dosage. Salvage Therapy. Transplantation Conditioning / methods. Whole-Body Irradiation
  • [MeSH-minor] Adolescent. Adult. Anti-Infective Agents / administration & dosage. Anti-Infective Agents / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Interleukin-2 Receptor alpha Subunit / immunology. Male. Middle Aged. Premedication. Prospective Studies. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822296.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antibodies, Monoclonal; 0 / IL2RA protein, human; 0 / Immunosuppressive Agents; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Myeloablative Agonists
  •  go-up   go-down


40. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H: Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer; 2010 Nov 15;116(22):5272-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
  • BACKGROUND: Despite advances in therapy, the majority of adult patients diagnosed with acute myeloid leukemia (AML) develop disease recurrence and die of their disease.
  • Reports have suggested an improved outcome in adult patients with AML using TST (at the cost of increased toxicity).
  • The current study was conducted to evaluate the feasibility and effectiveness of the intensively timed DCTER regimen for non-core-binding factor AML in adult patients aged <50 years.
  • The timed sequential DCTER regimen had a lower complete remission (CR) rate when compared with the IA combination,, (71% vs 80%, respectively), but this appeared to be counterbalanced by a higher long-term leukemia-free survival rate using the intensified regimen (48% vs 30%, respectively) in patients who achieved a CR (P = .06).
  • CONCLUSIONS: The intensively timed regimen of DCTER was found to induce durable remissions in adult patients with AML, including those patients with high-risk disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cytarabine / administration & dosage. Cytarabine / adverse effects. Cytarabine / therapeutic use. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Thioguanine / administration & dosage. Thioguanine / adverse effects. Thioguanine / therapeutic use

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] Blood. 1989 Jan;73(1):24-30 [2910362.001]
  • [Cites] Cancer Res. 1977 Jul;37(7 Pt 1):2138-46 [266416.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3903-10 [19131552.001]
  • [Cites] J Clin Oncol. 2010 Apr 10;28(11):1856-62 [20212254.001]
  • [Cites] Cancer. 2009 Dec 15;115(24):5746-51 [19795507.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2467-74 [15142880.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] J Clin Oncol. 1988 Mar;6(3):499-508 [3162515.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Am J Hematol. 2008 Nov;83(11):831-4 [18756545.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4116-24 [10361108.001]
  • [Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):11-8 [7799010.001]
  • [Cites] Ann Hematol. 2003 Nov;82(11):684-90 [12928754.001]
  • [Cites] Haematologica. 1999 Mar;84(3):226-30 [10189387.001]
  • [Cites] Am J Hematol. 2007 Dec;82(12):1056-62 [17696203.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):55-61 [15621781.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):116-24 [16721819.001]
  • (PMID = 20665501.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin; DCTER protocol
  •  go-up   go-down


41. Ma Y, Wang X, Xu X, Lin G: World Health Organization sub-types, initial treatment outcome and prognostic study of unselected adult patients with acute myeloid leukaemia in Shanghai: an analysis of 623 cases. J Int Med Res; 2009 Jul-Aug;37(4):1191-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] World Health Organization sub-types, initial treatment outcome and prognostic study of unselected adult patients with acute myeloid leukaemia in Shanghai: an analysis of 623 cases.
  • This study investigated the complete remission (CR) rate and survival of 623 newly diagnosed patients with acute myeloid leukaemia (AML) in Shanghai, China, classified according to World Health Organization and French-American-British criteria, and compared the differences in treatment effect with those reported in developed countries and those reported in Shanghai from 1984 to 1994.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. China / epidemiology. Female. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Male. Middle Aged. Prognosis. Remission Induction. Survival Rate. Treatment Outcome. World Health Organization. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761704.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M: Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases. Ann Oncol; 2008 Sep;19(9):1634-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases.
  • BACKGROUND: Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well characterized.
  • Complete remission was infrequent in the >or=60 age group.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Blood. 2003 Jul 1;102(1):43-52 [12623843.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:102-31 [14633779.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):161-6 [14695997.001]
  • [Cites] Blood. 1984 Sep;64(3):701-6 [6590097.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2412-21 [7919360.001]
  • [Cites] Oncology. 1999;56(2):160-3 [9949303.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Br J Haematol. 1999 Sep;106(4):1037-40 [10520009.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2781-7 [15571961.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):75-80 [15668479.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4179-91 [15961765.001]
  • [Cites] Semin Hematol. 2006 Apr;43(2):126-33 [16616046.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 1;168(1):50-8 [16772121.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):29-37 [17336252.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1431-5 [17460701.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1389-98 [17768113.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1275-81 [11911408.001]
  • [Cites] Breast Cancer. 2002;9(3):208-15 [12185331.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1599-604 [12400602.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):124-32 [12635175.001]
  • [Cites] Leukemia. 1993 Dec;7(12):1975-86 [8255096.001]
  • (PMID = 18467310.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA16056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2733065
  •  go-up   go-down


43. Di Bona E, Pogliani E, Rossi G, Lerede T, D'Emilio A, Vespignani M, Rodeghiero F, Barbui T, Bassan R: Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients. Leuk Lymphoma; 2005 Jun;46(6):879-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.
  • Idarubicin-based induction programs in acute lymphoblastic leukemia (ALL) account for 75?
  • -?85% of complete remission rate.
  • A small amount of patients exhibit primary refractoriness, and approximately 60% of those achieving a remission eventually relapse.
  • With 'A', 21 achieved a complete remission (CR), 10 were refractory and 5 died early.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Methotrexate / administration & dosage. Mitoxantrone / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Female. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019533.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; BZ114NVM5P / Mitoxantrone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


44. Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J: Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol; 2008 Sep;88(2):209-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
  • It was developed at the end of the nineties as 90% of the leukemic blast population of patients with acute myeloid leukaemia (AML) express the CD33 surface antigen (Dinndorf et al. [1] Blood 1986;67:1048-53).
  • CD33 antigen expression is also observed at diagnosis (in 15% of cases) (Pui et al. [3] J Clin Oncol 1998;16:3768-73) or at relapse (Guglielmi et al. [4] Leukemia 1997; 11:1501-7) of acute lymphoblastic leukaemia (ALL), representing a potential cellular target for ALL patients.
  • Case series have already demonstrated the efficacy of GO in children with relapsed CD33+ ALL with documentation of complete remission (CR) (Balduzzi et al. [5] Leukemia 2003;17:2247-8; Cotter et al. [6] Br J Haematol 2003;122:686-91; Zwaan et al. [7] Leukemia 2003;17:468-70).
  • In the other hand, there is no report at our knowledge of the use of GO in the setting of adult CD33+ ALL patient.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Fatal Outcome. Hematopoietic Stem Cell Transplantation. Humans. Male. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2004 Nov;89(11):1399-401 [15531467.001]
  • [Cites] Leukemia. 2003 Feb;17 (2):468-70 [12592351.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3768-73 [9850020.001]
  • [Cites] Blood. 1986 Apr;67(4):1048-53 [2937468.001]
  • [Cites] Br J Haematol. 2007 Oct;139(2):344-5 [17897313.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1003-7 [16038726.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):687-8 [12899727.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1557-8 [15229619.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2247-8 [12960967.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1501-7 [9305605.001]
  • (PMID = 18668307.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 93NS566KF7 / gemtuzumab
  •  go-up   go-down


45. Licinio J: The experience of bipolar disorder: a personal perspective on the impact of mood disorder symptoms. Mol Psychiatry; 2005 Sep;10(9):827-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For some diseases like acute lymphoblastic leukemia (ALL) of childhood, rates of remission and cure have been constantly advancing through better use of existing compounds.
  • [MeSH-minor] Adult. Humans. Male


46. Loh YS, Koh LP, Tai BC, Hwang WY, Linn YC, Goh YT, Tan PH: Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. Leuk Lymphoma; 2007 Jan;48(1):72-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation.
  • Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / therapy. Transplantation, Autologous. Transplantation, Homologous
  • [MeSH-minor] Acute Disease. Adult. Asian Continental Ancestry Group. Cause of Death. Follow-Up Studies. Graft vs Host Disease / etiology. Humans. Prognosis. Recurrence. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325850.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Cen D, Lü JX, Pei RZ, Tu ZG, Yu XL, Wen YA: [The clinical significance of real-time fluorescence PCR quantification of hepatocyte growth factor mRNA expression in acute leukemia]. Zhonghua Nei Ke Za Zhi; 2008 May;47(5):401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical significance of real-time fluorescence PCR quantification of hepatocyte growth factor mRNA expression in acute leukemia].
  • OBJECTIVE: To detect quantitatively hepatocyte growth factor (HGF) mRNA expressions of bone marrow mononuclear cells (MNCs) in acute leukemia (AL) and investigate its clinical significance.
  • RESULTS: Expressions of HGF mRNA in a group of AL were higher significantly than these in a control group (6.936 +/- 1.613, 0.407 +/- 0.170, P < 0.001), but there was similarity between a group of acute myeloid leukemia (AML) and group of acute lymphoblastic leukemia (ALL) (7.127 +/- 1.911, 6.635 +/- 0.934, P > 0.05).
  • In addition, expressions of HGF mRNA in the remission group were lower than these in the non-remission group (6.393 +/- 1.165, 8.041 +/- 1.848, P < 0.005).
  • [MeSH-major] Hepatocyte Growth Factor / genetics. Leukemia / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Child. Child, Preschool. Female. Fluorescence. Gene Expression Regulation, Leukemic. Humans. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953951.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


48. Tallman MS: New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program; 2005;:143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.
  • The prognosis for younger adults (< or = 55-60 years) with acute myeloid leukemia (AML) has improved during the last four decades.
  • Approximately 60%-80% of younger adults with AML achieve complete remission (CR) with the cytotoxic agents cytarabine and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304372.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / gemtuzumab
  •  go-up   go-down


49. Niedermeier DM, Frei-Lahr DA, Hall PD: Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy. Pharmacotherapy; 2005 Aug;25(8):1134-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute myeloid leukemia during the second and third trimesters of pregnancy.
  • Fortunately, the occurrence of acute myeloid leukemia (AML) during pregnancy is rare.
  • A 37-year-old woman in her second trimester (21 wks) of pregnancy was found to have acute myeloid leukemia.
  • Her hospital course was complicated by Pseudomonas vesicularis and gram-positive bacilli (not Bacillus anthracis) septicemia, but she obtained complete remission.
  • After a brief remission from a second induction, the patient died.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / therapeutic use. Cesarean Section. Cytarabine / therapeutic use. Female. Fetal Monitoring. Filgrastim. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Pregnancy. Pregnancy Outcome. Pregnancy Trimester, Second. Pregnancy Trimester, Third. Recombinant Proteins. Stem Cells / drug effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16207105.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


50. Hisatake J, Shimozuma J: [Hypercalcemia associated with all-trans retinoic acid therapy for microgranular type acute promyelocytic leukemia]. Rinsho Ketsueki; 2008 Jun;49(6):408-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypercalcemia associated with all-trans retinoic acid therapy for microgranular type acute promyelocytic leukemia].
  • The patient was diagnosed as having acute promyelocytic leukemia microgranular type (M3v) and was therefore administered all-trans retinoic acid (ATRA).
  • Complete remission was thereafter confirmed on day 45.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hypercalcemia / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects
  • [MeSH-minor] Adult. Drug Interactions. Drug Therapy, Combination. Fluconazole / adverse effects. Fluconazole / analogs & derivatives. Fluconazole / therapeutic use. Humans. Male. Organophosphates / adverse effects. Organophosphates / therapeutic use

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646608.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphates; 3JIJ299EWH / fosfluconazole; 5688UTC01R / Tretinoin; 8VZV102JFY / Fluconazole
  •  go-up   go-down


51. Zhao Y, Li HH, Bo J, Jing Y, Gao CJ, Wang QS, Yu L: [Significance of Id4 gene methylation in monitoring efficacy of allo-PBSCT for treatment of acute leukemias]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb;17(1):151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of Id4 gene methylation in monitoring efficacy of allo-PBSCT for treatment of acute leukemias].
  • This study was purposed to investigate the significance of Id4 gene methylation in monitoring the efficacy of allo-PBSCT for treatment of acute leukemias.
  • MS-PCR method was used to detect Id4 gene methylation in bone marrow samples from 29 patients with acute leukemia before and at 1, 3, 6 and 12 months after allo-PBSCT.
  • 20 patients with Id4 gene unmethylation after allo-PBSCT were in continuously complete remission status.
  • After allo-PBSCT, Id4 gene methylation status can be regarded as an indicator for predicting prognosis of acute leukemias.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236768.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins
  •  go-up   go-down


52. Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S: Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant; 2005 Nov;36(10):867-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.
  • The 5-year survival rates were 34% for patients in first complete remission (CR), 21% for those in second or subsequent CR, and 9% for those with active disease (P < 0.0001).
  • Severe acute GVHD increased the risk of treatment-related mortality (TRM) without diminishing the risk of relapse, whereas chronic GVHD reduced the risk of relapse without increasing the risk of TRM.
  • Thus, patients who developed extensive chronic GVHD had better survivals (P = 0.0217), and those who developed grade III-IV acute GVHD had worse survivals (P = 0.0023) than did the others.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Female. Graft vs Host Disease / mortality. Humans. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Recurrence. Registries. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Whole-Body Irradiation / statistics & numerical data


53. Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, Terre C, Gardin C, Hayette S, Preudhomme C, Dombret H: Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer; 2010 Apr 1;116(7):1725-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a first report, we have shown that priming with granulocyte-macrophage colony-stimulating factor (GM-CSF) may enhance complete remission (CR) rate and event-free survival (EFS) in younger adults with acute myeloid leukemia (AML).
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans. Middle Aged. Remission Induction. Risk

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143449.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


54. Păunică SC, Dumitriu A, Mogoş M, Georgescu O, Mogoş I: The evaluation of the periodontium in patients with leukemia using thermographic imaging. Hematology; 2009 Dec;14(6):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evaluation of the periodontium in patients with leukemia using thermographic imaging.
  • The results suggest that thermographic imaging could be used to reveal possible oral leukemic infiltrates when performed after therapeutic remission of specific infectious and inflammatory periodontal lesions.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Mouth Neoplasms / diagnosis. Periodontium. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Thermography
  • [MeSH-minor] Adult. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19941741.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ: Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant; 2005 Jan;11(1):65-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, treatment-related toxicity and, in patients with advanced MDS (refractory anemia with excess blasts [RAEB]; RAEB in transformation [RAEB-T]) or transformation to acute myeloid leukemia with multilineage dysplasia (tAML), posttransplantation relapse continue to be prevalent.
  • [MeSH-minor] Adolescent. Adult. Aged. Anemia, Refractory, with Excess of Blasts / therapy. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / therapy. Male. Middle Aged. Recurrence. Remission Induction / methods. Retrospective Studies. Severity of Illness Index. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625546.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA87948; United States / NHLBI NIH HHS / HL / HL 36444
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


56. Yavuz S, Paydas S, Disel U, Sahin B: IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience. Am J Ther; 2006 Sep-Oct;13(5):389-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
  • We evaluated efficacy and toxicity profiles of fludarabine, Ara-C, idarubicin, and G-CSF (Ida-FLAG) combination chemotherapy in 56 refractory and/or relapsed acute leukemia patients.
  • One third of the acute myeloblastic leukemia (AML) and 45% of acute lymphoblastic leukemia (ALL) cases were primary refractory disease.
  • In AML patients, complete remission (CR) was achieved in 15 cases (53.6%).
  • One case showed partial remission (PR) (3.6%) and 12 cases (42.8%) had resistant to this regimen (RD).
  • There was no correlation between response rate and leukemia subtype (AML versus ALL), leukocyte count, age, sex, disease status (de novo versus secondary), and RFS (early versus late relapse) (P > 0.05).
  • At present, only 3 patients are alive and 2 of these are in continuous remission.
  • In conclusion, Ida-FLAG is a good choice in cases with refractory/relapsing acute leukemia for salvage chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Protocols. Bone Marrow Transplantation. Cytarabine / administration & dosage. Drug Resistance, Neoplasm. Female. Humans. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Male. Middle Aged. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Survival Analysis. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988532.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


57. Kim DH, Sohn SK, Kim JG, Lee NY, Sung WJ, Baek JH, Suh JS, Lee KS, Lee KB: Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. Ann Hematol; 2005 Jan;84(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.
  • As such, the current study examined various parameters, including the cytogenetics at presentation and clinical disease status at transplantation, regarding their effect on the transplant outcomes of acute myeloid leukemia (AML) patients in an allogeneic peripheral blood stem cell transplantation (PBSCT) setting.
  • A total of 36 patients receiving an allogeneic PBSCT from matched sibling donors were included in a state of first complete remission (CR) (n=22, 61%) or beyond the first CR (n=14, 39%).
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Leukemia, Myeloid / therapy. Peripheral Blood Stem Cell Transplantation / methods. Predictive Value of Tests
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cytogenetic Analysis. Disease Progression. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Remission Induction. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15349754.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Chen CC, Yang CF, Lee KD, You JY, Yu YB, Ho CH, Tzeng CH, Chau WK, Hsu HC, Gau JP: Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities. Cancer Genet Cytogenet; 2007 Apr 15;174(2):138-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities.
  • Cytogenetics represents the most valuable predictor for a poor outcome in patients with acute myeloid leukemia (AML), but it encompasses a heterogeneous patient population who might have diverse pathogenesis and clinical courses.
  • The patients' performance status was the sole independent factor determining the complete remission rate among patients receiving standard induction chemotherapy.
  • On survival analysis, two factors independently predicted a longer overall survival: noncomplex karyotypes [vs. complex karyotypes, hazard ratio (HR) 0.434, 95% confidence interval (CI) 0.189-0.994, P = 0.048] and achievement of complete remission [(CR) vs. CR not reached, HR 0.170, 95% CI 0.051-0.572, P = 0.004)].
  • [MeSH-major] Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452256.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S, Shinjo K, Takeshita A, Ohno R, Ohnishi K: Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol; 2005 Oct;82(3):224-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
  • Recently, arsenic trioxide (ATO) has been proved to induce complete remission (CR) at a high rate in patients with acute promyelocytic leukemia (APL).
  • Initially, 0.15 mg/kg ATO was administered until bone marrow remission to a maximum of 60 days.
  • ATO therapy was remarkably effective for relapsed APL; however, postremission therapies were necessary to maintain a durable remission.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Arsenicals / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow / pathology. Female. Humans. Japan. Male. Middle Aged. Neoplasm Proteins / biosynthesis. Oncogene Proteins, Fusion / biosynthesis. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 2004 Mar;83(3):198-200 [15064871.001]
  • [Cites] Blood. 1997 Aug 1;90(3):967-73 [9242525.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]
  • [Cites] Ann Intern Med. 2000 Dec 5;133(11):881-5 [11103058.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Blood. 2016 Dec 29;128(26):3017 [28034863.001]
  • [Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Leukemia. 1993 Nov;7(11):1722-7 [8231241.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40 Suppl:S36-41 [9272132.001]
  • [Cites] Oncologist. 2001;6 Suppl 2:3-10 [11331434.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1704-9 [2224119.001]
  • [Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]
  • [Cites] Leukemia. 2002 Apr;16(4):617-22 [11960341.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(3):219-26 [11535988.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):558-61 [2170850.001]
  • [Cites] Leukemia. 1994;8 Suppl 3:S64-9 [7808028.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):120-6 [15534358.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]
  • [Cites] Ann Intern Med. 1999 Nov 16;131(10):797 [10577320.001]
  • [Cites] Leukemia. 2003 Oct;17(10):1930-3 [14513040.001]
  • (PMID = 16207595.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


60. Wei H, Tian Z, Wang XJ, Liu KQ, Zhang CP, Wang HJ, Mi YC, Wang JX: [Acute promyelocytic leukemia with CD59 deficiency]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute promyelocytic leukemia with CD59 deficiency].
  • The study was aimed to investigate whether CD59 is deficient in acute promyelocytic leukemia (APL) blast cells.
  • The results showed that the deficiency of CD59 expression in 12 out of 19 APL samples was found, its incidence was significantly higher than that in other acute myeloid leukemia (AML) samples (deficiency of CD59 expression in 14 of 40 non-APL AML samples, p=0.042).
  • The expression of CD59 became normal after the patients achieved complete remission (CR), which indicated that the deficient of CD59 expression was only found in APL blast cells, but also found in APL cell line NB4 cells.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Cd59 deficiency.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129240.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD59; 0 / Membrane Proteins; 0 / phosphatidylinositol glycan-class A protein; 5688UTC01R / Tretinoin
  •  go-up   go-down


61. Querques G, Russo V, Martinez A, Sarra GM, Iaculli C, Delle Noci N: [Retinal abnormalities in adult acute myeloid leukemia: semeiological features and prognostic correlations. Analysis of 178 cases]. J Fr Ophtalmol; 2007 Oct;30(8):819-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retinal abnormalities in adult acute myeloid leukemia: semeiological features and prognostic correlations. Analysis of 178 cases].
  • INTRODUCTION: Adult patients with acute myeloid leukemia (AML) frequently present retinal abnormalities.
  • PATIENTS AND METHODS: We examined 178 adult patients with newly diagnosed AML.
  • Among the younger patients (subgroup A), 78% of those with complete remission had no retinal findings (group 2) compared to 18% of the nonresponders.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / therapy. Retinal Diseases / epidemiology
  • [MeSH-minor] Adult. Aged. Aging / physiology. Humans. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome


62. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kröger N: Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol; 2009 Jan;37(1):135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Minimal residual disease (MRD) diagnostics in acute myeloid leukemia (AML) gain increasing importance after allogeneic stem cell transplantation (SCT).
  • [MeSH-major] Biomarkers, Tumor / genetics. Leukemia, Myeloid, Acute / genetics. Monitoring, Physiologic. Nuclear Proteins / genetics. Stem Cell Transplantation. Transplantation Chimera / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Mutation. Neoplasm, Residual. Recurrence. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction / methods. Time Factors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19100523.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
  •  go-up   go-down


63. Okumura H, Yamaguchi M, Kotani T, Sugimori N, Sugimori C, Ozaki J, Kondo Y, Yamazaki H, Chuhjo T, Takami A, Ueda M, Ohtake S, Nakao S: Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings. Eur J Haematol; 2007 Feb;78(2):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We treated two patients with acute myeloid leukemia (AML) and one patient with severe aplastic anemia (SAA) with HLA-mismatched stem cell transplantation (SCT) from NIMA-complementary donors (NIMA-mismatched SCT).
  • Grade III and grade IV acute GVHD developed in patients with AML on day 8 and day 11 respectively, and became a direct cause of death in one patient.
  • [MeSH-major] Anemia, Aplastic / surgery. Blast Crisis / surgery. Chimera / immunology. Graft Rejection / immunology. Graft vs Host Disease / immunology. HLA Antigens / genetics. Immunity, Maternally-Acquired. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Peripheral Blood Stem Cell Transplantation / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Tissue Donors. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cord Blood Stem Cell Transplantation. Disease Progression. Fatal Outcome. Female. Histocompatibility. Humans. Isoantigens / immunology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / pathology. Male. Remission Induction. Siblings. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives


64. Xicoy B, Ribera JM, Oriol A, Sanz MA, Abella E, Tormo M, del Potro E, Bueno J, Grande C, Fernández-Calvo J, Orts M, Novo A, Rivas C, Hernández-Rivas JM, Feliu E, Ortega JJ: [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]. Med Clin (Barc); 2006 Jan 21;126(2):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
  • BACKGROUND AND OBJECTIVE: T-cell acute lymphoblastic leukemia (ALL) includes 4 immunological subtypes: pro-T, pre-T, thymic or cortical and mature.
  • The objective of this study was to describe the clinical characteristics, the result of treatment and the prognosis of the immunological subtypes of T-cell ALL in 81 adult patients included in 2 protocols of the Spanish PETHEMA group (ALL-96 and ALL-93).
  • PATIENTS AND METHOD: Between 1993 and 2003, 81 adult patients from 22 Spanish hospitals were included in two PETHEMA protocols: ALL-96 for standard-risk patients, and ALL-93 for high- risk patients.
  • The main clinical and biological parameters as well as the rate of response to treatment, the frequency of complete remission , disease free survival and overall survival were compared in each T-cell ALL subtype.
  • Patients with mature T-cell ALL had a slow rate of response to treatment in comparison with patients wit pre-T and mature T-cell ALL but this did not translate to significant differences in frequency of complete remission (77% vs 94%), disease free survival (42% vs 46%) and overall survival (29% vs 47%).
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426542.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


65. Fujimaki K, Sakai R, Fujisawa S, Fujita H, Tanaka M, Hagihara M, Koharazawa H, Miyazaki T, Tomita N, Kanamori H, Maruta A, Ishigatsubo Y: [Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation]. Gan To Kagaku Ryoho; 2008 Jan;35(1):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Standard risk indicates acute leukemia in first or second remission and chronic myelocytic leukemia in first chronic phase, while high risk indicates all other diagnoses.
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Risk Factors. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18195534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


66. Marotta G, Tozzi M, Sammassimo S, Defina M, Raspadori D, Gozzetti A, Lauria F: Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia. Hematology; 2005 Oct;10(5):383-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia.
  • We used this therapeutic approach in a patient with high-risk acute myeloid leukemia in second complete remission (CR) with pre-existing hepatic aspergillosis refractory to conventional anti-fungal therapy.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Liver Diseases / drug therapy. Transplantation Conditioning
  • [MeSH-minor] Adult. Female. Humans. Liver / microbiology. Liver / radiography. Male


67. Zhang Y, Zhang MR, Yang L, Xiao ZJ: [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jul;27(7):470-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of nucleophosmin (NPM) gene mutation in patients with acute myeloid leukemia and myelodysplastic syndromes].
  • OBJECTIVE: To investigate nucleophosmin (NPM) gene mutations in patients with de novo acute myeloid leukemia (AML) with normal cytogenetics and primary myelodysplastic syndromes (MDS).
  • METHODS: Genomic DNA corresponding to exon 12 of NPM gene was amplified by polymerase chain reaction (PCR) in 40 AML patients (28 case untreated and 12 in first remission) and 33 MDS patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Myelodysplastic Syndromes / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Karyotyping. Male. Middle Aged. Mutation


68. Kondo T, Yasumoto A, Arita K, Sugita J, Shigematsu A, Okada K, Takahata M, Onozawa M, Kahata K, Takeda Y, Obara M, Yamamoto S, Endo T, Nishio M, Sato N, Tanaka J, Hashino S, Koike T, Asaka M, Imamura M: Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. Int J Hematol; 2010 Mar;91(2):310-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.
  • Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy.
  • If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option.
  • Moreover, there was no relapse in patients with favorable cytogenetics who were in hematological remission prior to RIST.
  • Thus, RIST for AML patients with favorable cytogenetics in remission is safe and effective.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Cytogenetics. Disease-Free Survival. Female. Graft vs Host Disease / mortality. Humans. Karyotyping. Male. Middle Aged. Retrospective Studies. Risk Factors. Survival Analysis. Young Adult


69. Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ: Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol; 2009 Aug 1;27(22):3634-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.
  • PURPOSE: Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care.
  • RESULTS: After median of 8.3 years of follow-up, 5-year overall survival (OS), leukemia-free survival (LFS), and relapse were 29% (95% CI, 26% to 32%), 26% (95% CI, 23% to 29%), and 43% (95% CI, 39% to 47%), respectively.
  • HCT in first complete remission (CR1) yielded significantly better outcomes than later HCT.
  • Acute graft-versus-host disease was associated with fewer relapses.
  • HCT in early remission can best exploit the potent antileukemic efficacy of allografting from UCB, RD, or URD sources.
  • [MeSH-major] Graft vs Host Disease / diagnosis. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Graft Rejection. Graft Survival. Humans. Kaplan-Meier Estimate. Male. Multivariate Analysis. Probability. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Severity of Illness Index. Survival Analysis. Time Factors. Tissue Donors. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome. Young Adult


70. Usvasalo A, Räty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E, Kauppila M, Koistinen P, Parto K, Riikonen P, Salmi TT, Silvennoinen R, Elonen E, Saarinen-Pihkala UM: Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica; 2008 Aug;93(8):1161-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in adolescents and young adults in Finland.
  • BACKGROUND: Interest has recently been paid to adolescents and young adults with acute lymphoblastic leukemia, particularly because all reports so far published indicate that these patients have a better outcome when treated with pediatric rather than adult therapeutic protocols.
  • There are different biological subtypes of acute lymphoblastic leukemia with distinct features and prognoses; the distribution of these subtypes is not well known among adolescents.
  • We, therefore, studied acute lymphoblastic leukemia in adolescents and young adults aged 10 to 25 years in Finland.
  • DESIGN AND METHODS: This population-based study included 225 consecutive patients aged 10-25 years diagnosed with acute lymphoblastic leukemia during 1990-2004.
  • One hundred and twenty-eight patients (10-16 years) were treated with pediatric Nordic (NOPHO) protocols, and 97 patients (17-25 years) with Finnish Leukemia Group National protocols.
  • RESULTS: For the whole cohort, the remission rate was 96%, 5-year event-free survival 62% and overall survival 72%.
  • The 5-year event-free survival was 67% for the pediatric treatment group and 60% for the adult treatment group (p=n.s.).
  • CONCLUSIONS: Unlike all previous studies, we found that the outcome of adolescents and young adults with acute lymphoblastic leukemia treated with pediatric or adult therapeutic protocols was comparable.
  • The success of the adult acute lymphoblastic leukemia therapy emphasizes the benefit of central referral of patients to academic centers and adherence to research protocols.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Blast Crisis. Child. Disease-Free Survival. Female. Finland. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukocyte Count. Male. Phenotype. Philadelphia Chromosome. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Aug;93(8):1124-8 [18669975.001]
  • (PMID = 18556413.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


71. Niimi K, Hashimoto Y, Kurokawa S, Okada A, Tozawa K, Kohri K: Embryonal rhabdomyosarcoma of the prostate. Int J Clin Oncol; 2010 Feb;15(1):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of embryonal rhabdomyosarcoma of the prostate in a 20-year-old man with a history of acute lymphatic leukemia at 6 years of age.
  • The tumor shrank, and partial remission was obtained after 1 course of chemotherapy.
  • During treatment for acute lymphatic leukemia at the age of 6 years, the patient had been exposed to a cumulative radiation dose of 10 Gy across his entire body.
  • [MeSH-major] Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adult. Humans. Male. Neoplasms, Radiation-Induced


72. Morimoto A, Imamura T, Ishii R, Nakabayashi Y, Nakatani T, Sakagami J, Yamagami T: Successful management of severe L-asparaginase-associated pancreatitis by continuous regional arterial infusion of protease inhibitor and antibiotic. Cancer; 2008 Sep 15;113(6):1362-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: L-asparaginase is a key drug in the treatment of childhood acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).
  • Significantly, chemotherapy could be resumed within 4 weeks (range, 12-23 days) after the onset of AAP, and the patients were in complete remission from 4 months to 44 months with further chemotherapy that excluded L-asparaginase.
  • [MeSH-minor] Child. Child, Preschool. Drug Therapy, Combination. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Neoplasm Recurrence, Local / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18661511.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Protease Inhibitors; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


73. Nanri T, Uike N, Kawakita T, Iwanaga E, Mitsuya H, Asou N: A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation. Genes Chromosomes Cancer; 2010 Mar;49(3):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.
  • Here, we describe a Japanese family in which two individuals with acute myeloid leukemia (AML) and one healthy individual had an identical 4-base pair insertion in the N-terminal region of CEBPA (350_351insCTAC), resulting in the termination at codon 107 (I68fsX107).
  • These C-terminal mutations disappeared upon remission in both patients.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-alpha / genetics. Leukemia, Myeloid, Acute / genetics. Mutation
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA Primers. DNA, Neoplasm / genetics. Female. Germ-Line Mutation. Humans. Male. Middle Aged. Mutagenesis, Insertional. Pedigree. Polymerase Chain Reaction. Sequence Deletion


74. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood; 2007 Jul 15;110(2):727-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
  • Acquired imatinib resistance in advanced Philadelphia-positive acute lymphoblastic leukemia (Ph(+) ALL) has been associated with mutations in the kinase domain (KD) of BCR-ABL.
  • Patients enrolled in the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) trial ADE10 for newly diagnosed elderly Ph(+) ALL were retrospectively examined for the presence of BCR-ABL KD mutations by denaturing high-performance liquid chromatography (D-HPLC), cDNA sequencing, and allele-specific polymerase chain reaction (PCR).
  • P-loop mutations predominated and were not associated with an inferior hematologic or molecular remission rate or shorter remission duration compared with unmutated BCR-ABL.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Mutation. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405907.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


75. Plensa E, Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández Ribas JM, Moreno MJ, del Potro E, Tormo M, Rivas C, Besalduch J, Sanz MA, Arias J, Fernández Calvo J, Moraleda JM, Bueno J, Feliu E, Ortega JJ, Grupo PETHEMA: [Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia]. Med Clin (Barc); 2005 Sep 3;125(7):241-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia].
  • BACKGROUND AND OBJECTIVE: The prognostic value of myeloid antigen expression in adult acute lymphoblastic leukemia (ALL) is controversial.
  • The frequency of myeloid antigen expression, its association with other clinical and biologic variables and the prognostic significance in terms of complete remission (CR) rate, event free survival (EFS) and overall survival (OS) were analyzed.
  • CONCLUSIONS: In this study, myeloid antigen expression did not have prognostic influence in adult patients with high risk ALL.
  • [MeSH-major] Antigens, CD / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunophenotyping. Male. Prevalence. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137483.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


76. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S: Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer; 2009 Dec 1;115(23):5490-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
  • BACKGROUND: Dose intensification of chemotherapy has improved outcome for younger adults with de novo acute lymphoblastic leukemia (ALL).
  • Four of 7 patients who achieved a CR underwent subsequent allogeneic stem cell transplantation in remission.
  • [MeSH-minor] Adult. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Recurrence. Salvage Therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19708032.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone
  • [Other-IDs] NLM/ NIHMS676514; NLM/ PMC4458381
  •  go-up   go-down


77. Ferrara F, Izzo T, Criscuolo C, Riccardi C, Celentano M, Mele G: Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results. Am J Hematol; 2010 Sep;85(9):687-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
  • The strategy named double induction (DI) in acute myeloid leukemia (AML) consists of two courses of chemotherapy irrespective of the degree of cytoreduction in the bone marrow (BM) after the first course, unless severe complications prohibit its application.
  • Overall, complete remission (CR) was achieved in 20/30 patients (67%), while eight patients (27%) were refractory and two died of infectious complications.
  • Our study suggest that D15 driven DI represents a feasible and effective therapeutic strategy in young adult AML patients, improving therapeutic results and not compromising feasibility of allo-SCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Blast Crisis / therapy. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Chromosome Aberrations. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Mutation. Remission Induction. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Young Adult

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20652967.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


78. Palmieri S, D'Arco AM, Celentano M, Mele G, Califano C, Pollio F, D'Amico MR, Ferrara F: An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients. Ann Oncol; 2006 Jul;17(7):1146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.
  • BACKGROUND: Conflicting results have been reported about the prognostic relevance of antecedent myelodysplastic syndrome (MDS) in acute myeloid leukemia (AML) of older adults.
  • RESULTS: Complete remission rate, death in induction and primary resistance were not statistically different between the two groups.


79. Barr P, Fu P, Lazarus H, Kane D, Meyerson H, Hartman P, Reyes R, Creger R, Stear K, Laughlin M, Tse W, Cooper B: Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leuk Lymphoma; 2007 Oct;48(10):1940-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.
  • Ten of 42 (24%) patients achieved a complete remission (CR or CRp).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Thalidomide / administration & dosage. Topotecan / administration & dosage. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic. Thrombocytopenia / chemically induced. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917962.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA43703
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A; 4Z8R6ORS6L / Thalidomide; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


80. Maha A, Cheong SK, Leong CF, Seow HF: Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy. Malays J Pathol; 2009 Dec;31(2):81-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
  • We examined the expression pattern of proinflammatory cytokines, signaling molecules of the PI3K and MAPK pathways molecules and death receptor, DR5 on paired samples at diagnosis and during chemotherapy in acute myeloid leukaemia patients treated with cytosine arabinoside and daunorubicin.
  • The results were correlated with remission status one month after chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Leukemia, Myeloid, Acute / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cytarabine / administration & dosage. Cytokines / drug effects. Cytokines / genetics. Cytokines / metabolism. Daunorubicin / administration & dosage. Elafin / drug effects. Elafin / genetics. Elafin / metabolism. Female. Humans. Male. Middle Aged. Mitogen-Activated Protein Kinases / drug effects. Mitogen-Activated Protein Kinases / genetics. Mitogen-Activated Protein Kinases / metabolism. Prognosis. RNA, Messenger / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / drug effects. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism. Remission Induction. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514850.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Elafin; 0 / PI3 protein, human; 0 / RNA, Messenger; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 04079A1RDZ / Cytarabine; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


81. Advani AS, Lim K, Gibson S, Shadman M, Jin T, Copelan E, Kalaycio M, Sekeres MA, Sobecks R, Hsi E: OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma; 2010 Apr;51(4):606-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia.
  • OCT-2 and its co-activator, BOB.1, are B-cell associated transcription factors expressed in a subset of patients with acute myeloid leukemia (AML).
  • On multivariate analysis, co-expression of OCT-2/BOB.1 remained predictive for achievement of complete remission (HR 0.44, p = 0.010) and increased risk of relapse (HR 2.30, p = 0.047).
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Octamer Transcription Factor-2 / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Female. Gene Expression Regulation, Leukemic. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141429.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Octamer Transcription Factor-2; 0 / POU2AF1 protein, human; 0 / POU2F2 protein, human; 0 / Trans-Activators
  •  go-up   go-down


82. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, Réa D, Cayuela JM, Vekemans MC, Reman O, Buzyn A, Pigneux A, Escoffre M, Chalandon Y, MacIntyre E, Lhéritier V, Vernant JP, Thomas X, Ifrah N, Dombret H, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL): Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood; 2007 Feb 15;109(4):1408-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.
  • The combination of imatinib with chemotherapy has been recently reported as very promising in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
  • During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL).
  • Overall, complete remission (CR) and BCR-ABL real-time quantitative polymerase chain reaction (RQ-PCR) negativity rates were 96% and 29%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Philadelphia Chromosome. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Benzamides. Cytarabine / therapeutic use. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Mitoxantrone / therapeutic use. Neoplasm, Residual. Remission Induction. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062730.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 04079A1RDZ / Cytarabine; 8A1O1M485B / Imatinib Mesylate; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


83. Litzow MR: Evolving paradigms in the therapy of Philadelphia-chromosome-negative acute lymphoblastic leukemia in adults. Hematology Am Soc Hematol Educ Program; 2009;:362-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving paradigms in the therapy of Philadelphia-chromosome-negative acute lymphoblastic leukemia in adults.
  • Important studies challenging previous approaches to the treatment of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) have emerged in the past decade.
  • Donor versus no donor comparisons of allogeneic transplant highlight a potent graft-versus-leukemia effect in ALL, and the application of reduced-intensity conditioning transplants may exploit this effect while reducing non-relapse mortality.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008222.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 70
  •  go-up   go-down


84. Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, Karasuno T, Mitani K, Kodera Y, Yamagami T, Koga D: Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma; 2010 Oct;51(10):1855-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia.
  • After achieving complete remission (CR), 34 patients (69.4%) were determined to be positive and 15 (30.6%) were negative for WT1.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / genetics. RNA, Messenger / blood. WT1 Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Young Adult


85. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med; 2007 Jul 26;357(4):340-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 184 patients, 116 had complete remission of disease without relapse during a median follow-up of 48 months (range, 14 to 118).
  • Acute leukemia developed in three additional patients after therapy.
  • [MeSH-minor] Adolescent. Adult. Algorithms. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / therapy. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2007 Oct 25;357(17):1771-2; author reply 1773-4 [17960020.001]
  • [CommentIn] N Engl J Med. 2007 Oct 25;357(17):1772-3; author reply 1773-4 [17969228.001]
  • [CommentIn] N Engl J Med. 2007 Oct 25;357(17):1773; author reply 1773-4 [17969229.001]
  • [CommentIn] Eur Urol. 2007 Dec;52(6):1795-6 [18074440.001]
  • [CommentIn] Nat Clin Pract Oncol. 2008 Mar;5(3):126-7 [18043602.001]
  • [CommentIn] Nat Clin Pract Urol. 2008 Feb;5(2):78-9 [18073725.001]
  • [CommentIn] N Engl J Med. 2007 Oct 25;357(17):1773; author reply 1773-4 [17969230.001]
  • (PMID = 17652649.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


86. Jiang N, Li H, Wang GS, Zhang J, Zhang JF, Yi SH, Yang Y, Cai CJ, Lu MQ, Chen GH: Acute leukemia, a rare but fatal complication after liver transplantation. Leuk Res; 2009 Oct;33(10):1349-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia, a rare but fatal complication after liver transplantation.
  • Little information is available about the risk factors and means to improve the survival rate of acute leukemia in a rare but often fatal complication after liver transplantation (LT).
  • The patient, a 42-year-old man who developed acute leukemia 38 months after liver transplantation, was successfully treated with chemotherapy and has subsequently been in remission.
  • Only 16 patients with acute leukemia after liver transplantation have been reported, and the mortality rate is extraordinarily high (52.94%, 9/17).
  • More cases of acute leukemia will emerge as the rate of survival after liver transplantation increases.
  • The patient's chromosomal mutation profile, the choice of immunosuppressive agent, and infection by hepatitis virus may be the risk factors for the development of acute leukemia after LT.
  • [MeSH-major] Leukemia / epidemiology. Liver Transplantation / adverse effects
  • [MeSH-minor] Adult. Aged. Bone Marrow / pathology. Child. Child, Preschool. Female. Humans. Immunosuppressive Agents / therapeutic use. Liver Diseases / classification. Liver Diseases / surgery. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446880.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


87. Mori H, Sakai H, Sanada M, Shimamoto K, Sasaki S, Azuma R, Higuchi T, Harada H, Niikura H, Omine M, Fujita K, Takahashi N: [Clinical analysis of HLA-DR-negative non-M3 AML]. Rinsho Ketsueki; 2007 Jul;48(7):547-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The type of leukemia was defined as HLA-DR(-) non-M3-AML, when HLA antigens were detected by flow cytometry at an incidence of < 20% of the blast population excluding M3-AML.
  • Out of 109 patients with de novo acute myeloid leukemia, 8 patients had HLA-DR(-) non-AML-M3.
  • All of 7 patients who underwent induction therapy attained complete remission.
  • [MeSH-major] HLA-DR Antigens / analysis. Leukemia, Myeloid, Acute / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Flow Cytometry. Humans. Leukemia, Promyelocytic, Acute / immunology. Leukemia, Promyelocytic, Acute / mortality. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695303.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / HLA-DR Antigens
  •  go-up   go-down


88. Lin P, Chen L, Luthra R, Konoplev SN, Wang X, Medeiros LJ: Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol; 2008 Aug;21(8):1029-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations.
  • Acute myeloid leukemia with t(8;21)(q22;q22) is a distinct type of leukemia considered to have a favorable prognosis.
  • We studied 56 patients with acute myeloid leukemia associated with t(8;21) and correlated clinicopathologic, cytogenetic and molecular findings with outcome to identify markers of prognosis.
  • At the last follow-up, 29 patients had died, 25 patients were in complete remission and two patients were alive with disease.
  • The 5-year overall survival rate of patients with mutated leukemia was 20%.
  • We conclude that acute myeloid leukemia associated with t(8;21) is a heterogeneous disease with poor survival in a subset of patients unrelated to common secondary cytogenetic aberrations.
  • [MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adolescent. Adult. Aneuploidy. Biomarkers, Tumor / metabolism. Chromosome Deletion. Female. Humans. Male. Prognosis. Sex Chromosomes. Survival Rate. Texas / epidemiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536654.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


89. Geng SX, DU X, Weng JY, Zhong LY, Guo R, Lu ZS, Chen ZH: [Expression of antiapoptotic gene aven in de novo acute myeloid leukemia patients and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1424-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of antiapoptotic gene aven in de novo acute myeloid leukemia patients and its clinical significance].
  • This study was aimed to investigate the aven mRNA expression level of leukocytes from peripheral blood(PB)of de novo patients with acute myeloid leukemia (AML) and analyze its clinical significance, so as to provide a experimental basis for evaluating prognosis.
  • The complete remission (CR) rate after two cycles of chemotherapy in patients with lower aven mRNA level (25/30, 83.33%) was higher than that in patients with higher aven mRNA level(21/30, 70%), but the difference was not significant(p = 0.22).

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030919.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AVEN protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


90. Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA, Cancer and Leukemia Group B: Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant; 2009 Sep;44(6):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Auto-SCT for AML in second remission: CALGB study 9620.
  • We studied the feasibility and efficacy of a two-step approach to Auto-SCT for patients with AML in second remission.
  • The most important prognostic factor was cytogenetics, with acute promyelocytic leukemia (APL) patients having a 5-year DFS of 67% compared with 16% for others.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Aging. Antigens, CD34 / analysis. Combined Modality Therapy / adverse effects. Disease-Free Survival. Female. Humans. Ideal Body Weight. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Remission Induction. Transplantation, Autologous. Treatment Outcome. Treatment Refusal. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289999.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA29165; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


91. Bareford D, Odeh B, Narayanan S, Wiltshire S: Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin. Transfus Med; 2005 Oct;15(5):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin.
  • A 40-year-old patient, who was a Jehovah's Witness, with acute myeloid leukaemia entered remission using a chemotherapeutic based regime aided by the addition of gemtuzumab ozogamicin without requiring any blood product support.
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Jehovah's Witnesses. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Humans. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202062.001).
  • [ISSN] 0958-7578
  • [Journal-full-title] Transfusion medicine (Oxford, England)
  • [ISO-abbreviation] Transfus Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab
  •  go-up   go-down


92. Xu Q, Wang M, You Q, Wang H, Ye K, Zhan R, Zhou Y: Isolated recurrence of granulocytic sarcoma-two case reports-. Neurol Med Chir (Tokyo); 2009 Dec;49(12):611-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 29-year-old male presented with an extra- and intracranial mass 10 years after bone marrow transplantation for chronic myeloid leukemia.
  • A 34-year-old female presented with an intracranial mass 3 years after complete remission of acute myeloid leukemia-M2a.
  • The first patient received adequate postoperative radiotherapy and chemotherapy, and achieved complete remission without evidence of diseases during the 6-month follow up.
  • The second patient only received whole brain radiotherapy, failed to respond, and died of systemic leukemia later.
  • [MeSH-major] Head and Neck Neoplasms / etiology. Head and Neck Neoplasms / pathology. Leukemia, Myeloid, Acute / complications. Neoplasm Recurrence, Local / pathology. Sarcoma, Myeloid / etiology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Brain Neoplasms / etiology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Combined Modality Therapy / methods. Drug Therapy. Early Diagnosis. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Radiotherapy. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035140.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Li SX, Da WM, Gao CJ, Zhu HY, Wang SH, Bo J, Jing Y, Jin HJ: [Detection of engraftment evidence after allogeneic hematopoietic stem cell transplantation by STR-PCR]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb;13(1):25-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 10 patients were keeping continuance of remission, 4 patients died and one patient relapsed but still alive.
  • Mixed chimerism is a prophetic role for leukemia relapse and chimera status guides the treatment.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748430.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


94. Nasir TA, Kabir A: Chemotherapy induced toxicities in therapeutic trials of Acute Lymphoblastic Leukaemia. Mymensingh Med J; 2005 Jan;14(1):61-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy induced toxicities in therapeutic trials of Acute Lymphoblastic Leukaemia.
  • It is common practice in therapeutic trials in Acute Lymphoblastic Leukaemia (ALL) to treat chemotherapy induced toxicities.
  • Remission induction, consolidation and maintenance therapy with conventional combination chemotherapy and CNS prophylaxis with intrathecal methotrexate and radiotherapy were instituted to all patients for long term event free survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695958.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Bangladesh
  •  go-up   go-down


95. Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar M: Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res; 2007 Jun;31(6):791-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
  • We evaluated FLT3 protein and its phosphorylation in the plasma from 85 patients with AML, 16 patients with myelodysplastic syndrome (MDS) and 5 patients with acute lymphoblastic leukemia (ALL).
  • However, amongst the patients without FLT3 mutations, those with a higher level of phosphorylated FLT3 had a significantly shorter duration of remission (p=0.04).
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Protein Processing, Post-Translational. fms-Like Tyrosine Kinase 3 / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Differentiation / genetics. Cell Proliferation. Female. Hematopoietic Stem Cells. Humans. Male. Membrane Proteins / genetics. Middle Aged. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Phosphorylation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Remission Induction


96. Zhao JN, Qiao ZH, Xu LR, Lu QY, Niu XQ, Zhang P, Wang Z: [Expression of FLT3 internal tandem duplication in pediatric patients with acute myeloid leukemia and its correlation with multidrug resistance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb;17(1):23-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of FLT3 internal tandem duplication in pediatric patients with acute myeloid leukemia and its correlation with multidrug resistance].
  • This study was aimed to investigate the expression of FLT3 internal tandem duplication (FLT3-ITD) in pediatric patients with acute myeloid leukemia (AML) and to analyse the clinical features of patients with mutations and the relation of FLT3-ITD with multidrug resistance gene 1 (mdr1).
  • The results indicated that the FLT3-ITDs were detected in 8 out of 81 pediatric patients (9.88%) and all mutations detected were hybrid, while less frequently this mutation was detected in adult patients.
  • The patients with FLT3-ITD had lower induction remission rate (only 25%), but the patients without FLT3-ITD had higher remission rate (76.1%).
  • It is concluded that the FLT3-ITD is frequent mutation in pediatric patients with AML, the prognosis is worse and the induction remission rate is lower in these patients, but the FLT3-ITD not relates with the mdr1, which suggests that the common MDR modulators may be un effective for therapy of the patients with FLT3-ITD.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236740.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


97. Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M: Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant; 2008 May;14(5):568-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
  • We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI).
  • Ten patients were Philadelphia chromosome-positive (Ph(+)) and 35 patients were in complete remission (CR) at transplantation.
  • Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively.
  • No patient developed grade IV acute GVHD (aGVHD) or died of GVHD.
  • Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Graft vs Host Disease. Humans. Male. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410899.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


98. Basak G, Torosian T, Snarski E, Niesiobedzka J, Majewski M, Gronkowska A, Urbanowska E, Jedrzejczak W: Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia. Ann Transplant; 2010 Apr-Jun;15(2):68-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.
  • BACKGROUND: The T315I mutation of BCR/ABL gene is known to produce complete resistance of chronic myelogenous leukemia (CML) to all currently available BCR/ABL inhibitors.
  • Despite satisfactory hematological remission, he failed to achieve complete cytogenetic remission within the first year of treatment.
  • The course of transplantation was complicated by staphylococcal sepsis, grade I skin acute GvHD and limited chronic skin GVHD.
  • However, the goal of alloSCT was achieved and the patient remains in complete molecular remission at week +68 post-transplantation.
  • [MeSH-major] Genes, abl. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Mutation, Missense
  • [MeSH-minor] Adult. Amino Acid Substitution. Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Humans. Leukemia, Myeloid, Accelerated Phase / drug therapy. Leukemia, Myeloid, Accelerated Phase / genetics. Leukemia, Myeloid, Accelerated Phase / therapy. Male. Protein Kinase Inhibitors / pharmacology. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20657522.001).
  • [ISSN] 2329-0358
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


99. Niu Y, Chen SC, Jiang B, Li DG, Ge CW, Li RS: [Erythroleukemia - a subtype of myelodysplastic syndrome?]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):219-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to study whether erythroleukemia was really a subtype of acute leukemia, the clinical laboratory characteristics and development of disease in 21 cases of erythroleukemia were analyzed.
  • 11/19 cases (57.4%) achieved remission (CR 10; PR 1) after chemotherapy.
  • The median remission length were 6 months for CR patients and 2 months for PR patients, but most of CR patients displayed obvious displasia of bone marrow and cytopenia of blood in the period of CR.


100. Xiang Y, Wang XB, Sun SJ, Guo AX, Wei AH, Cheng YB, Huang SL: [Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Jul;30(7):440-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia].
  • OBJECTIVE: To report the results of curative and adverse effects of compound huangdai tablet (CHDT) as induction therapy for 193 patients with acute promyelocytic leukemia (APL).
  • RESULTS: One hundred and ninety-three patients achieved complete remission (CR), 78.8% of whom in 30 to 60 days with an average time of 44.3 d.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Phytotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Plant Preparations / adverse effects. Plant Preparations / therapeutic use. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954593.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down






Advertisement